Zhejiang East Asia Pharmaceutical Co., Ltd. (SHA:605177)
23.40
+0.60 (2.63%)
Sep 2, 2026, 2:19 PM CST
SHA:605177 Revenue
Zhejiang East Asia Pharmaceutical had revenue of 201.57M CNY in the quarter ending June 30, 2026, a decrease of -10.39%. This brings the company's revenue in the last twelve months to 990.47M, up 2.55% year-over-year. In the year 2025, Zhejiang East Asia Pharmaceutical had annual revenue of 940.19M, down -21.54%.
Revenue (ttm)
990.47M
Revenue Growth
+2.55%
P/S Ratio
2.59
Revenue / Employee
654.21K
Employees
1,514
Market Cap
2.57B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 940.19M | -258.05M | -21.54% |
| Dec 31, 2024 | 1.20B | -158.21M | -11.66% |
| Dec 31, 2023 | 1.36B | 176.89M | 15.00% |
| Dec 31, 2022 | 1.18B | 467.34M | 65.62% |
| Dec 31, 2021 | 712.22M | -169.45M | -19.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.15B |
| Shandong Sito Bio-technology | 1.12B |
| Guiyang Xintian Pharmaceutical | 723.26M |
| Landfar Bio-medicine | 660.26M |
| Jilin Jian Yisheng Pharmaceutical | 650.83M |
| Hubei Goto Biopharm Group | 650.05M |
| Suzhou Fushilai Pharmaceutical | 394.29M |
| Yantai Zhenghai Biotechnology | 336.07M |